NASDAQ: VTYX
Ventyx Biosciences Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their VTYX stock forecasts and price targets.

Forecast return on equity

Is VTYX forecast to generate an efficient return?

Company
-22.73%
Industry
140.86%
Market
89.98%
VTYX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VTYX forecast to generate an efficient return on assets?

Company
-20.77%
Industry
32.43%
VTYX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VTYX earnings per share forecast

What is VTYX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.77
Avg 2 year Forecast
-$1.76
Avg 3 year Forecast
-$1.55

VTYX revenue forecast

What is VTYX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$91.7M
Avg 2 year Forecast
$47.2M
Avg 3 year Forecast
$249.7M

VTYX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VTYX$2.56N/AN/A
VYGR$3.30$14.43+337.36%Strong Buy
LRMR$2.88$17.50+507.64%Strong Buy
CDXS$2.23N/AN/A
LCTX$0.81$4.25+424.69%Strong Buy

Ventyx Biosciences Stock Forecast FAQ

What is VTYX's earnings growth forecast for 2025-2027?

(NASDAQ: VTYX) Ventyx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.

Ventyx Biosciences's earnings in 2025 is -$123,990,000.On average, 6 Wall Street analysts forecast VTYX's earnings for 2025 to be -$125,834,352, with the lowest VTYX earnings forecast at -$148,726,910, and the highest VTYX earnings forecast at -$97,490,845. On average, 5 Wall Street analysts forecast VTYX's earnings for 2026 to be -$125,243,714, with the lowest VTYX earnings forecast at -$160,824,314, and the highest VTYX earnings forecast at -$46,254,781.

In 2027, VTYX is forecast to generate -$109,944,056 in earnings, with the lowest earnings forecast at -$165,093,986 and the highest earnings forecast at -$35,580,601.

If you're new to stock investing, here's how to buy Ventyx Biosciences stock.

What is VTYX's revenue growth forecast for 2026-2028?

(NASDAQ: VTYX) Ventyx Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.

Ventyx Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VTYX's revenue for 2026 to be $6,526,193,744, with the lowest VTYX revenue forecast at $6,526,193,744, and the highest VTYX revenue forecast at $6,526,193,744. On average, 2 Wall Street analysts forecast VTYX's revenue for 2027 to be $3,355,606,433, with the lowest VTYX revenue forecast at $185,019,123, and the highest VTYX revenue forecast at $6,526,193,744.

In 2028, VTYX is forecast to generate $17,766,105,442 in revenue, with the lowest revenue forecast at $583,521,848 and the highest revenue forecast at $34,948,689,035.

What is VTYX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VTYX) forecast ROA is -20.77%, which is lower than the forecast US Biotechnology industry average of 32.43%.

What is VTYX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VTYX) Ventyx Biosciences's current Earnings Per Share (EPS) is -$1.75. On average, analysts forecast that VTYX's EPS will be -$1.77 for 2025, with the lowest EPS forecast at -$2.09, and the highest EPS forecast at -$1.37. On average, analysts forecast that VTYX's EPS will be -$1.76 for 2026, with the lowest EPS forecast at -$2.26, and the highest EPS forecast at -$0.65. In 2027, VTYX's EPS is forecast to hit -$1.55 (min: -$2.32, max: -$0.50).

What is VTYX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VTYX) forecast ROE is -22.73%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.